Mode
Text Size
Log in / Sign up

Compound heterozygous mutations in NPHP4 gene identified in a patient with nephronophthisis and proteinuriaGenetic Testing Reveals New Mutations in Kidney Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that genetic testing can identify pathogenic mutations in the NPHP4 gene for diagnosing nephronophthisis.

This case report describes a single Chinese patient presenting with nephronophthisis and proteinuria. The authors utilized whole exome sequencing and Sanger sequencing to investigate the underlying genetic etiology of the condition.

The analysis identified compound heterozygous mutations in the NPHP4 gene: c.2611C>T (p.R871X) and c.2768G>A (p.R923H). The p.R871X variant was classified as pathogenic, while the p.R923H variant was classified as likely pathogenic. These findings suggest a genetic basis for the patient's clinical presentation.

A primary limitation of this evidence is the small sample size, as it is based on a single case report. Therefore, these specific mutations and their implications cannot be generalized to the broader population of patients with nephronophthisis. However, the report highlights the utility of genetic testing in providing accurate diagnoses and identifying novel mutations within the NPHP4 gene.

Researchers studied a Chinese patient with nephronophthisis, a rare genetic kidney disease that causes proteinuria. The patient underwent whole exome sequencing and Sanger sequencing to identify the genetic cause.

The analysis found two mutations in the NPHP4 gene: one classified as pathogenic and the other as likely pathogenic. These mutations were inherited in a compound heterozygous pattern, meaning the patient received one from each parent.

This is a single case report, so the findings cannot be generalized to all patients with nephronophthisis. However, it demonstrates how genetic testing can help confirm a diagnosis and identify specific mutations that may be relevant for family counseling.

No safety concerns were reported, as this was a genetic analysis, not a treatment study. The main takeaway is that genetic testing can be a valuable tool for diagnosing rare kidney diseases, but more research is needed to understand how these mutations affect larger populations.

What this means for you:
Genetic testing can identify rare mutations causing kidney disease, but this is a single case, not generalizable.

Common questions

What is nephronophthisis?

Nephronophthisis is a rare genetic kidney disease that leads to progressive kidney damage and proteinuria. It is caused by mutations in several genes, including NPHP4.

What did the genetic testing find?

The testing found two mutations in the NPHP4 gene: one pathogenic (p.R871X) and one likely pathogenic (p.R923H). The patient had inherited one from each parent.

Is this study relevant to all kidney disease patients?

No, this is a single case report, so the results apply only to this patient. Genetic testing may help others with similar symptoms, but more research is needed.

Study Details

Study typeGuideline
EvidenceLevel 5
PublishedJul 2026
View Original Abstract ↓
Nephronophthisis (NPHP), an autosomal recessive kidney disorder characterized by chronic tubulointerstitial nephritis, is the most prevalent monogenic cause of end-stage renal disease (ESRD). Previous studies have identified variants in more than 20 genes, designated NPHP1 to NPHP20, and in additional loci as the genetic causes of NPHP. Here, a Chinese patient who presented with NPHP and proteinuria was enrolled. By employing whole exome sequencing and Sanger sequencing, we identified a rare compound heterozygous mutation in the NPHP4 gene (c.2611C > T/p.R871X and c.2768G > A/p.R923H) in the patient. Sanger sequencing further confirmed that the p.R871X variant was inherited from the father and that the p.R923H variant originated from the mother. Both variants were predicted to be deleterious by bioinformatic software. In accordance with the American College of Medical Genetics and Genomics guideline, the p.R871X variant was classified as pathogenic, and the p.R923H variant was classified as likely pathogenic. So far, neither of these mutations has been reported in patients with NPHP. Our findings contribute to the precise diagnosis of the patient and further underscore the utility of genetic testing in the accurate diagnosis of NPHP.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.